BEIJING, Feb. 08, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to conduct clinical trials of ICP-538, a VAV1-directed molecular glue degrader (MGD). This is the first VAV1 degrader approved to enter clinical trials in China and the second globally. Read More
Source link
Thai Stocks Tied to Incumbent PM Anutin Jump on Surprise Win
The stock jumped as much as 22% on Monday, the most since Sept. 2024, after preliminary results showed Bhumjaithai Party secured 191 seats in the 500-member parliament. It is among…





